Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial-Reference-Cited by-同舟云学术

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

Published:2024-05 Issue:5 Volume:25 Page:588-602
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Oaknin Ana,Moore Kathleen,Meyer Tim,López-Picazo González José,Devriese Lot A,Amin Asim,Lao Christopher D,Boni Valentina,Sharfman William H,Park Jong Chul,Tahara Makoto,Topalian Suzanne L,Magallanes Manuel,Molina Alavez Alejandro,Khan Tariq Aziz,Copigneaux Catherine,Lee Michelle,Garnett-Benson Charlie,Wang Xuya,Naumann R Wendel

Publisher

Elsevier BV

Reference22 articles.

1. Global cancer in women: burden and trends;Torre;Cancer Epidemiol Biomarkers Prev,2017

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide;Walboomers;J Pathol,1999

4. Immunotherapy against cancer-related viruses;Tashiro;Cell Res,2017

5. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers;Mezache;Mod Pathol,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the Gap: Immune Checkpoint Inhibitor as an Option in the Management of Advanced and Recurrent Cervical Cancer in Sub-Saharan Africa;Cureus;2024-09-10

2. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I);Taiwanese Journal of Obstetrics and Gynecology;2024-09

3. Cervical cancer: a new era;International Journal of Gynecologic Cancer;2024-08-07

4. Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy;Frontiers in Oncology;2024-08-05

5. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer;Cancer Drug Resistance;2024-06-11